June 24, 2020

Cytiva upgrades Massachusetts contract biomanufacturing site with increased capacity and automation technologies

By Colleen Connolly, Senior Communications Manager
  • Cytiva’s Fast Trak biomanufacturing services advances pre-clinical through Phase II development and manufacturing
  • CDMO facility offers cutting-edge automation capabilities and flexible solutions for biotechnology companies

June 24, 2020

Cytiva is celebrating the completion of an extensive renovation to its Fast Trak cGMP contract biomanufacturing and process development site in Marlborough, Massachusetts, USA. The upgraded facility is 60,000 square feet (5,600 square meters) and has bioprocessing capabilities ranging in scale from 10L to 2000L. Biotechnology companies looking for assistance in bringing therapeutics to market faster can leverage the extensive technical support and single-use biomanufacturing expertise available at this enhanced site.

Olivier Loeillot, Senior Vice President, BioProcess at Cytiva, says: “Biotechnology companies are increasingly outsourcing their manufacturing, whether to access expertise, capacity, or both. Our upgraded Fast Trak cGMP facility will provide our customers, particularly the small to mid-size companies, with the services and expertise needed to help expedite their processes and get to market faster.”

Cytiva’s Fast Trak services team has been accelerating customer projects for more than 17 years, completing more than one hundred production campaigns in one of six global biomanufacturing sites. Outsourcing the development of enhanced processing platforms can streamline tech transfer and accelerate capacity expansion programs. With an extensive understanding of bioprocessing, Fast Trak scientists can improve productivity with attention to costs and regulatory compliance. Biomanufacturers working with Fast Trak maintain control over their intellectual property and can place “people-in-plant” for full understanding of the process.

The site utilizes Cytiva’s Figurate automation platform that includes exceptional control and communication capabilities which can turn data insights into productive outcomes for both upstream and downstream processes efficiency gains.

More than 70 percent of the clinical trials planned for the US in 2020 will be Phase I and II1, with over 50% of companies outsourcing at least some bioprocessing, and 19% outsourcing more than half2. The upgraded Fast Trak cGMP facility has capacity to serve this growing need from small to mid-sized biotechnology companies.

About Cytiva

Cytiva is a 3.3 billion USD global life sciences leader with nearly 7,000 employees across 40 sites dedicated to advancing and accelerating therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients.

2BioPlan Associates

Media Contact:

Colleen Connolly
[email protected]
+1 774 245 3893